Literature DB >> 12030732

Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine.

J Behr1, B Degenkolb, F Krombach, C Vogelmeier.   

Abstract

Extracellular glutathione deficiency and exaggerated oxidative stress may contribute to the pathogenesis of fibrosing alveolitis (FA). High-dose N-acetylcysteine (NAC) supplementation partially reverses extracellular glutathione depletion and oxidative damage, but effects on intracellular glutathione are unknown. Intracellular total glutathione (GSHt) and activation of bronchoalveolar lavage cells (BAC) obtained from 18 FA patients (9 males, aged 52+/-2 yrs), before and after 12 weeks of oral NAC (600 mg t.i.d.), were assessed. Eight healthy nonsmokers (2 males, aged 36+/-6 yrs) served as a control group. Intracellular GSHt was decreased in FA (1.57+/-0.20 nmol 1x10(6) BAC(-1) versus 2.78+/-0.43 nmol x 10(6) BAC(-1)). After NAC treatment, the intracellular GSHt content increased (1.57+/-0.20 versus 1.87+/-0.19 nmol x 1 x 10(6) BAC(-1)). The spontaneous oxidative activity of BAC decreased after NAC treatment (2.7+/-0.8 versus 1.0+/-0.2 nmol x 1 x 10(6) BAC(-1) x h(-1)). Interleukin-8 concentration (82.1+/-31.5 versus 80.0+/-22.6 pg x mL bronchoalveolar fluid (BALF), nonsignificant (NS)) and myeloperoxidase activity (1.93+/-0.64 versus 1.55+/-0.47 mU x mL(-1) BALF, NS) did not change significantly, but were found to be inversely correlated to intracellular GSHt. In conclusion, high-dose N-acetylcysteine supplementation increases intracellular glutathione levels slightly. This increase is associated with a mild reduction of oxidative activity but not with a reduction of bronchoalveolar cell activation in these patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12030732     DOI: 10.1183/09031936.02.00204902

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  21 in total

Review 1.  Targeted therapy for systemic sclerosis: how close are we?

Authors:  Manuel Ramos-Casals; Vicent Fonollosa-Pla; Pilar Brito-Zerón; Antoni Sisó-Almirall
Journal:  Nat Rev Rheumatol       Date:  2010-04-13       Impact factor: 20.543

Review 2.  N-acetylcysteine -- passe-partout or much ado about nothing?

Authors:  Mirja-Liisa Aitio
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

Review 3.  Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy.

Authors:  Vuokko L Kinnula; Cheryl L Fattman; Roderick J Tan; Tim D Oury
Journal:  Am J Respir Crit Care Med       Date:  2005-05-13       Impact factor: 21.405

4.  Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum.

Authors:  Brian H Harvey; Charise Joubert; Jan L du Preez; Michael Berk
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

Review 5.  Focus on antioxidant enzymes and antioxidant strategies in smoking related airway diseases.

Authors:  V L Kinnula
Journal:  Thorax       Date:  2005-08       Impact factor: 9.139

6.  High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis.

Authors:  Rabindra Tirouvanziam; Carol K Conrad; Teodoro Bottiglieri; Leonore A Herzenberg; Richard B Moss; Leonard A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

Review 7.  Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis.

Authors:  Rui-Ming Liu
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

8.  Amifostine reduces lung vascular permeability via suppression of inflammatory signalling.

Authors:  P Fu; A A Birukova; J Xing; S Sammani; J S Murley; J G N Garcia; D J Grdina; K G Birukov
Journal:  Eur Respir J       Date:  2008-11-14       Impact factor: 16.671

Review 9.  Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis.

Authors:  R-M Liu; K A Gaston Pravia
Journal:  Free Radic Biol Med       Date:  2009-10-02       Impact factor: 7.376

Review 10.  Antifibrosis: to reverse the irreversible.

Authors:  Ziv Paz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.